S&P 500 Healthcare Sector SEC Filings — March 05, 2026

05-03-2026

TriSalus Life Sciences reported Q4 2025 revenue of $13.2M, up 60% YoY from $8.3M and 14% QoQ, with full-year 2025 revenue of $45.2M, up 53% YoY from $29.4M, exceeding original guidance. However, full-year gross margin declined to 84.6% from 86.1% due to lower manufacturing efficiency on new products, operating expenses rose with S&M up $2.9M and G&A up $3.5M YoY, and net loss attributable to common stockholders widened to $69.7M from $33.2M primarily from preferred stock conversion effects. The company raised $46M gross proceeds from a public offering post-Q4, ending 2025 with $20.4M in cash, and reaffirmed 2026 revenue guidance of $60-62M.

• ·R&D expenses decreased $2.7M YoY to $15.0M for FY 2025.
• ·S&M expenses increased $2.9M YoY to $28.7M for FY 2025.
• ·G&A expenses increased $3.5M YoY to $21.5M for FY 2025, including $1.8M accelerated stock-based compensation.
• ·Q4 gross margin improved to 86.7% from 85.3% YoY.
• ·Appointed Michael Stansky to Board in February 2026.
• ·Hosted KOL events on Nov 12, 2025 (Uterine Fibroids) and Dec 15, 2025 (Symptomatic Thyroid Disease).

05-03-2026

ProCap Financial, Inc. (BRRWW) filed a DEFA14A additional proxy statement on March 05, 2026, containing standard disclaimers on forward-looking statements and clarifying that it does not constitute an offer to sell securities. The filing provides media contact Erica Chase and investor relations email. No specific proxy proposals, financial metrics, or material updates are detailed in the provided content.

05-03-2026

Canadian Pacific Kansas City Limited announced via press release that its wholly owned subsidiary, Canadian Pacific Railway Company, is issuing $600M of 4.000% notes due 2029 and $600M of 5.500% notes due 2056, for a total of $1.2B. The offering is expected to close on March 6, 2026, subject to customary closing conditions.

• ·Filing dated March 5, 2026, reporting event of March 4, 2026
• ·Securities registered: Common Shares on NYSE (CP) and TSX (CP); Perpetual 4% Debentures on NYSE (CP40) and LSE (BC87)

05-03-2026

Moderna, Inc. entered into a Settlement Agreement on March 3, 2026, with Arbutus Biopharma Corporation and Genevant Sciences entities, resolving all worldwide patent infringement litigation related to Spikevax® and mRESVIA®, while securing a fully paid-up, royalty-free license for its infectious disease portfolio including mNEXSPIKE® and mCOMBRIAX®. The agreement requires a $950M noncontingent payment by July 8, 2026, and a potential additional $1.3B contingent payment based on the outcome of Moderna's appeal to the Federal Circuit regarding §1498 defenses for U.S. Government contract doses, providing litigation certainty but at a substantial near-term cost.

• ·Settlement includes mutual releases and covenants not to sue on Arbutus/Genevant patents for Moderna’s SM-102-based LNP infectious disease vaccines.
• ·If Moderna prevails fully on §1498 appeal, no contingent payment due; if affirmed against Moderna, full $1.3B due; Arbutus/Genevant must repay with interest if later overturned.
• ·Full Settlement Agreement to be filed as exhibit to Q1 2026 10-Q.

05-03-2026

News Corporation disclosed via 8-K information provided to the Australian Securities Exchange (ASX) regarding its ongoing $1B stock repurchase program authorizing purchases of Class A (NWSA) and Class B (NWS) common stock. No specific repurchase transactions or amounts were detailed in the filing itself, with details in Exhibits 99.1 and 99.2. The disclosures are made daily to ASX as required, alongside quarterly and annual reports.

• ·Event date: March 4, 2026
• ·Filing date: March 5, 2026
• ·Securities: Class A Common Stock (NWSA, par value $0.01), Class B Common Stock (NWS, par value $0.01) on Nasdaq Global Select Market

05-03-2026

Bank of New York Mellon Corp's 2026 DEF 14A proxy statement seeks advisory approval of 2025 NEO compensation, emphasizing strong performance under CEO Robin Vince with annualized adjusted revenue growth of 6%, noninterest expense growth of 3%, and operating EPS growth of 18% from 2022-2025, resulting in 178% total shareholder return outperforming the S&P 500 Financials Index by over 2.5x. Prior three-year say-on-pay proposals received average 95% stockholder support. No declines or flat metrics were highlighted in the disclosed performance data.

• ·Compensation for Mses. O’Connor and Robinson includes amounts for roles as Chair and member of the Board of BNY Mellon Government Securities Services Corp.
• ·Proxy seeks approval pursuant to Item 402 of Regulation S-K.

05-03-2026

Lakeland Financial Corp (LKFN) filed its DEF 14A proxy statement on March 5, 2026, for the annual shareholder meeting on April 14, 2026, at 3:30 p.m. ET, held virtually. Proposals include the election of 13 director nominees, non-binding approval of executive officer compensation, and ratification of Crowe LLP as independent auditors for the year ending December 31, 2026, with the board recommending a FOR vote on all items.

• ·Shareholders can request proxy materials by March 31, 2026, via www.ProxyVote.com, 1-800-579-1639, or sendmaterial@proxyvote.com.
• ·Virtual meeting access: www.virtualshareholdermeeting.com/LKFN2026.

05-03-2026

Ciena reported fiscal Q1 2026 revenue of $1.43B, up 33% YoY from $1.07B, with adjusted EPS rising 111% to $1.35; Optical Networking drove growth to $1.02B (up from $728M). However, GAAP gross margin dipped 0.2 points to 43.8%, operating expenses increased 11.5% to $436.1M, and Blue Planet Automation revenue declined to $20.4M from $26M YoY. The company raised FY2026 revenue guidance to $5.9B-$6.3B (28% YoY growth at midpoint) and repurchased $80.5M in shares.

• ·Three customers each >10% of revenue totaled 47.4% in Q1 FY2026.
• ·Q2 FY2026 revenue guidance: $1.5B +/- $50M.
• ·Cash increased to $1.12B from $1.09B QoQ as of Jan 31, 2026.

05-03-2026

First Business Financial Services, Inc. highlighted strong 2025 performance in its proxy statement for the April 24, 2026 Annual Meeting, with core deposit and loan balances growing 11% and 8% YoY over 2024, respectively, total revenue up 10%, and efficiency ratio improving to 58.78%. The company reported over 14% growth in pre-tax pre-provision earnings, EPS, and tangible book value per share, alongside a robust ROATCE of 15.3%, all exceeding strategic targets. Five-year TSR through December 31, 2025 reached 235%, outperforming peers (66% median), Russell 2000 (73%), and S&P 500 Banks (125%).

• ·2026 Annual Meeting virtually on April 24, 2026 at 10:00 a.m. CDT via www.meetnow.global/M6YH2SP
• ·Proposals: Elect three Class I directors to serve until 2029 Annual Meeting; approve 2026 Equity Incentive Plan; non-binding advisory vote on compensation
• ·Leadership transition: Dave Seiler to assume CEO role in May 2026 following Corey Chambas retirement (announced May 2025)
• ·Peer group: publicly traded banks with assets between $1.75B and $7.0B

05-03-2026

On February 27, 2026, Valerie O. Murray, President of Beacon Trust Company and Executive Vice President and Chief Wealth Management Officer of Provident Bank (subsidiaries of Provident Financial Services, Inc.), announced her resignation effective May 22, 2026, to pursue other opportunities, with no disagreement on company matters. Under the Separation Agreement, she will be on garden leave from March 27 to May 22, 2026, continuing to receive base salary and benefits, and is entitled to a $1.2M lump sum payment subject to conditions including a release of claims. The company expressed appreciation for her leadership and contributions.

• ·Filing date: March 5, 2026
• ·Garden leave period: March 27, 2026 to May 22, 2026
• ·Resignation announcement date: February 27, 2026

05-03-2026

PacBio (NASDAQ: PACB) announced on March 5, 2026, the appointment of Christopher Gibson, Ph.D., co-founder and Chairman of Recursion (NASDAQ: RXRX), to its Board of Directors to strengthen expertise in AI-driven biology and data tools for HiFi sequencing. CEO Christian Henry stated that Gibson's experience scaling AI-native life sciences will support PacBio's vision of integrating sequencing, computation, and data-driven discovery. Gibson expressed enthusiasm for leveraging PacBio's high-quality long-read sequencing datasets with AI analytics to accelerate healthcare advancements.

• ·Filing date: March 05, 2026
• ·PacBio products are for Research Use Only, not for diagnostic procedures

05-03-2026

Six Flags Entertainment Corporation announced definitive agreements to divest seven parks to EPR Properties for $331M in cash consideration, with the divested parks generating $260M in net revenue and $45M in Adjusted EBITDA from 4.5M guests in FY2025. Proceeds, after taxes and expenses, will pay down debt and slightly improve the leverage ratio while sharpening focus on higher-return remaining parks. No significant guest impact expected during transition, with operations continuing normally through 2026.

• ·Transaction expected to close by end of Q1 or beginning of Q2 2026, subject to closing conditions and third-party approvals.
• ·EPR retains Six Flags brand usage through end of 2026.
• ·Perella Weinberg Partners acted as financial advisor; Weil, Gotshal & Manges LLP as legal counsel to Six Flags.
• ·Parks currently total 26 amusement parks, 15 water parks, and 9 resort properties across 16 states in U.S., Canada, and Mexico, plus one managed in Saudi Arabia.

05-03-2026

Caribou Biosciences reported Q4 and FY 2025 financial results, with licensing and collaboration revenue increasing 12% YoY to $11.2M for the full year, driven by prior IP licenses, while R&D expenses decreased 16% to $109.4M and G&A expenses fell 18% to $37.9M due to workforce reductions and pipeline prioritization. However, GAAP net loss remained relatively flat at $148.1M for FY2025 (vs. $149.1M in 2024), including a $21.3M non-recurring non-cash impairment charge, and cash reserves dropped 43% to $142.8M, sufficient into 2H 2027 but prompting exploration of funding options for the vispa-cel pivotal trial. Clinical updates highlighted positive data for vispa-cel in 2L LBCL and CB-011 dose expansion in r/r MM, with additional data expected in 2026.

• ·Non-GAAP FY 2025 net loss of $126.8M ($1.36 per share) excludes $21.3M impairment, improving from $149.1M ($1.65 per share) in FY 2024.
• ·Q4 2025 GAAP net loss per share $0.28 vs. $0.39 in Q4 2024.
• ·Cash expected to fund operations into 2H 2027, including CB-011 dose expansion and vispa-cel pivotal trial start-up activities.

05-03-2026

Guidewire Software reported Q2 FY2026 total revenue of $359.1M, up 24% YoY, driven by 33% growth in subscription and support revenue to $237.2M and 30% increase in services revenue to $62.4M; however, license revenue declined 7% YoY to $59.5M. ARR reached $1.121B, reflecting 22% YoY growth, with strong profitability including GAAP operating income of $38.4M (vs $11.7M prior) and the company raising its FY2026 outlook across key metrics. Cash and equivalents decreased to $1.351B from $1.483B at prior quarter-end amid share repurchases.

• ·GAAP net income $60.1M in Q2 FY2026 vs net loss of $37.3M in Q2 FY2025.
• ·Non-GAAP diluted EPS $1.17 in Q2 FY2026 vs $0.51 prior year.
• ·Q3 FY2026 outlook: Total revenue $352M-$358M; FY2026 total revenue $1.438B-$1.448B.
• ·FY2026 operating cash flow outlook $360M-$375M.

05-03-2026

Amalgamated Financial Corp. (AMAL) reported total assets of $8.5B as of December 31, 2025, up from $8.3B in 2024, with net interest income growing 5.4% YoY to $297.8M on higher loan volumes (+$25.2M interest income) and total interest income up 5.2% to $422.2M at a 5.09% yield. However, non-interest income declined 6.9% YoY to $30.9M amid losses on securities sales and equity investments, while non-interest expenses rose 7.9% to $172.2M driven by higher compensation, professional fees, and technology costs; nonperforming assets also edged up slightly to $28.7M or 0.32% of assets.

• ·Average total loans grew to $4,720M in 2025 from $4,479M in 2024 (+5.4% YoY).
• ·Nonaccrual loans in commercial portfolio rose to $22.1M from $16.0M YoY.
• ·Allowance for credit losses on loans to total loans declined to 1.16% from 1.29% YoY.
• ·Service charges on deposit accounts dropped sharply to $17.5M from $32.2M YoY.

05-03-2026

CIMG Inc. entered into an Amended and Restated Equity Transfer Agreement on February 27, 2026, to acquire 100% of Daren Business Technology Limited (100 ordinary shares) from Shelei Jiang for zero cash consideration, with closing expected by March 31, 2026, subject to customary conditions. Post-closing, the Company may issue up to 74,487,896 common shares to seller designees Dundas Technology Limited and Kellyview Investment Limited by April 10, 2026, contingent on stockholder approval and audited revenue targets through September 30, 2029; unmet targets result in forfeiture, but full issuance would cause significant dilution with no assurance of approval.

• ·Acquisition amends and restates prior Equity Transfer Agreement dated February 11, 2026.
• ·Award Shares subject to Nasdaq Listing Rule 5635 stockholder approval and transfer restrictions with leak-out tied to RMB-denominated revenue targets.
• ·Shares, if issued, rely on Regulation S and Section 4(a)(2) exemptions as restricted securities.
• ·Filed as Exhibit 10.1: full A&R Equity Transfer Agreement.

05-03-2026

Costco Wholesale Corporation reported second quarter fiscal 2026 net sales of $68.24B, up 9.1% YoY from $62.53B, with comparable sales rising 7.4% (adjusted 6.7%), driven by strong Other International (13.0%) and digitally-enabled sales (22.6%), while U.S. comp sales grew more modestly at 5.9%. Net income increased to $2.04B ($4.58 diluted EPS) from $1.79B ($4.02), and year-to-date sales grew 8.7% to $134.22B. February net sales rose 9.5% to $21.69B, positively impacted by a 0.5% shift from later Lunar/Chinese New Year.

• ·Operates 924 warehouses globally, including 634 in U.S./Puerto Rico, 114 in Canada, and expansions in Other International.
• ·Membership fees Q2: $1.36B (up from $1.19B YoY).
• ·Cash provided by operating activities for 24 weeks: $7.68B (up 28% YoY).
• ·Total assets as of Feb 15, 2026: $83.64B (up from $77.10B at Aug 31, 2025).
• ·Conference call scheduled for March 5, 2026 at 2:00 p.m. PT.

05-03-2026

Net interest income rose $4.7M YoY to $51.2M for 2025, with net interest margin expanding to 3.12% from 2.73%, driven by favorable rates despite lower volumes. However, average loans declined to $1.35B from $1.43B, total interest income fell $2.0M to $87.6M, and nonperforming assets increased to $16.7M from $14.3M. Non-interest income grew 10.25% to $11.1M supported by gains on loan sales (+32%), while non-interest expenses edged up 1.49% to $42.9M.

• ·Capital ratios remain strong: Total capital 14.6% (2025) vs 15.6% (2024), all well above well-capitalized thresholds.
• ·CRE portfolio: $443M Non-Owner Occupied, $240M Owner-Occupied, with criticized loans at 1.4%-7.9% of segments.
• ·Net loan recoveries of $58k in 2025 vs net charge-offs of $100k in 2024; NCOs (annualized) 0.00% vs (0.01)%.

05-03-2026

South Plains Financial, Inc. reported net income of $58.5M for the year ended December 31, 2025, up 17.6% YoY from $49.7M in 2024, supported by net interest income growth of 13.6% to $167.0M and total assets expansion of 5.9% to $4.48B. However, noninterest income declined 6.6% to $44.9M, primarily due to a $3.5M drop in mortgage banking activities, while noninterest expense rose 4.0% to $132.6M. Credit quality strengthened with nonperforming assets falling to 0.26% of total assets from 0.58%, and efficiency ratio improved to 62.32%.

• ·Provision for credit losses increased 20.8% YoY to $5.2M in 2025.
• ·Net interest margin expanded to 3.98% from 3.65% YoY.
• ·Common equity tier 1 capital ratio strengthened to 14.45% from 13.53%.
• ·Total risk-based capital ratio slightly declined to 17.26% from 17.86%.
• ·Allowance for credit losses on loans stable at 1.44% of total loans (up from 1.42%).

05-03-2026

Ellington Financial Inc. issued a press release on March 5, 2026, announcing its estimated book value per share of common stock as of January 31, 2026, furnished under Item 7.01 to satisfy Regulation FD requirements. The press release is included as Exhibit 99.1 but does not disclose the specific book value figure in the filing body. No comparative or quantitative details on book value changes were provided.

• ·Filing includes securities registered on NYSE: Common Stock (EFC), Series B Preferred (EFC PR B), Series C Preferred (EFC PR C), Series D Preferred (EFC PRD).

05-03-2026

NewLake Capital Partners reported fourth quarter 2025 revenue of $12.3 million, down 1.4% YoY from $12.5 million due to vacancies at properties previously leased to AYR Wellness and Revolutionary Clinics, while full-year 2025 revenue increased 1.9% YoY to $51.1 million driven by acquisitions and rent escalations. AFFO declined 3.0% YoY in Q4 to $10.6 million ($0.51 per share) but rose modestly 0.3% for the full year to $43.8 million ($2.09 per share), with net income per share flat at $0.29 in Q4 and up slightly to $1.28 FY. The company declared a first quarter 2026 dividend of $0.43 per share and completed acquisitions totaling $1.7 million.

• ·Portfolio includes one property classified as Real Estate Held for Sale.
• ·Total liquidity of $106.3M includes $82.4M available under Revolving Credit Facility.
• ·No debt maturities until May 2027; $7.6M outstanding borrowings at 7.75% interest.
• ·Acquired two dispensaries from Cresco Labs in Ohio for $785K total and one from Curaleaf in PA for $950K via like-kind exchange.
• ·Hartford, CT property marketed for sale with lease amendments to C3 Industries.
• ·Cannabist operating under forbearance agreement extended through March 6, 2026.

05-03-2026

Via Renewables, Inc. reported total revenues of $463.5M for FY 2025, up 16% YoY from $398.9M in 2024, driven by 58% higher natural gas volumes, while Adjusted EBITDA rose 23% to $72.3M and Retail Gross Margin increased 6% to $149.8M with strong natural gas segment growth (+27% to $60.8M). However, net income declined 42% to $35.6M from $61.1M amid higher depreciation/amortization and operating expenses, Retail Electricity Gross Margin fell 5% to $88.9M, cash from operations dropped 17% to $42.1M, and RCE attrition worsened to 4.2%.

• ·Electricity volumes sold increased 9.0% YoY in 2025 vs 2024.
• ·Natural gas volumes sold surged 58.4% YoY in 2025 vs 2024.
• ·Customer acquisition costs rose to $10.4M in 2025 from $9.5M in 2024.
• ·Distributions/dividends paid increased to $30.3M in 2025 from $10.7M in 2024.
• ·Non-POR Credit Loss as % of Revenue improved to 0.5% in 2025 from 1.3% in 2024.